Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology c

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primar

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d

Takeda's psoriasis drug zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a Phase 3

Takeda ((TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-bl

If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with m

Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions

Takeda eyes growth with FDA Priority Reviews for narcolepsy and PV drugs. Get the latest on TAK'

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.28 per share which beat the analy

TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (

FDA clears Axsome's Auvelity for Alzheimer's agitation, backed by Phase 3 data, expanding it

Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2

Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipelin

Under the terms of the agreement, Axsome obtained worldwide commercial, development, and manufacturi

Takeda Canada Inc. ("Takeda") is pleased to announce new data from the two pivotal Phase 3 s

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at wee

Global CEOs signal cautious China expansion as Eli Lilly ramps investment, while the Supreme Court r

https://www.bloomberg.com/news/articles/2026-03-23/takeda-lilly-rejected-by-supreme-court-on-actos-f

https://asia.nikkei.com/business/pharmaceuticals/takeda-pharma-to-cut-400-us-jobs-in-overhaul-ahead-

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Pat

Takeda shares are down slightly on Friday morning after positive Phase 3 Entyvio data show strong re

Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, whic

FDA grants Breakthrough Therapy status to Rybrevant for advanced cancer while Trellus Health extends

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Differe

Takeda partners with AI biotech Iambic to speed drug discovery in cancer and inflammation, with pote

Takeda Canada Inc. ("Takeda") is pleased to announce that Ontario Drug Benefit (ODB) include

Takeda missed Q3 earnings estimates as Vyvanse generic pressure weighed on sales, but raised its 202

Takeda Pharmaceutical Co (NYSE:TAK) lowers FY2025 GAAP EPS guidance from $0.66 to $0.64. Lowers FY20

Takeda Pharmaceutical Co (NYSE:TAK) lowers FY2025 Adj EPS guidance from $3.25 to $3.16 vs $1.64 anal

FY2025 OutlookUpdating Full Year Management Guidance for Revenue and ForecastsTakeda has updated its

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.47 per share which missed the ana

CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding t

Takeda ((

Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab

Under the terms of its January 2024 worldwide license and collaboration agreement with Takeda, the s

Takeda's royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will b

Takeda reports positive Phase 3 data for psoriasis drug zasocitinib, beating placebo and Otezla, wit

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoint

Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules)

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Contro

FDA reports rare neutralizing antibodies, including a pediatric death, in patients treated with Take

Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but

After 4.5 years, two doses of QDENGA provided 61.2% [95% CI: 56.0, 65.8] vaccine efficacy (VE) in pr

Takeda posts lower Q2 earnings and trims 2025 outlook as Vyvanse generics, FX headwinds, and impairm